About us

HomeAbout us
ABOUT CELLPOINT

TOWARDS AFFORDABLE AND
WIDELY AVAILABLE CAR-T

Engineered patient T cells using chimeric antigen receptors (CAR-Ts) are a great invention from the last decade, eradicating tumors and providing durable remissions. However, first generation CAR-Ts require shipment of cryopreserved cells to large factories and labor-intensive manual processing, as designed in the ’90s.

  • It takes 1-2 months while patients can not wait due to cancer progression.
  • T cells don’t like freezing and lengthy processing outside the body.
  • It also takes > 300,000 USD/EUR per treatment, limiting wide patient access.
  • At CellPoint, we designed an unconventional CAR-T manufacturing and supply model using the best technology.
    • CellPoint will disrupt time-to-treatment and costs completely

    Our Vision & mission

    CD19 CAR-T

    60,000 + patients in need yearly

    BCMA CAR-T

    40,000 + patients in need yearly

    Plug and play

    Follow up CARs in development

    Low costs

    Point-of-care supply will drop
    costs per treatment

    Treat when needed

    Flexible scheduling and
    short vein-to-vein

    Low patient drop-out

    Rapid treatment of
    progressive patients